Identification of novel androgen receptor target genes in prostate cancer

被引:76
|
作者
Jariwala, Unnati
Prescott, Jennifer
Jia, Li
Barski, Artem
Pregizer, Steve
Cogan, Jon P.
Arasheben, Armin
Tilley, Wayne D.
Scher, Howard I.
Gerald, William L.
Buchanan, Grant
Coetzee, Gerhard A.
Frenkel, Baruch [1 ]
机构
[1] Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA
[2] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA
[3] Univ So Calif, Keck Sch Med, Dept Urol, Los Angeles, CA USA
[4] Univ So Calif, Keck Sch Med, Dept Orthopaed Surg, Los Angeles, CA USA
[5] Univ Adelaide, Hanson Inst, Sch Med, Dame Roma Mitchell Canc Res Labs, Adelaide, SA, Australia
[6] Joan & Sanford I Weill Coll Med, Dept Med, Mem Sloan Kettering Canc Ctr, Div Solid Tumor Oncol,Genitourinary Oncol Serv, New York, NY USA
关键词
D O I
10.1186/1476-4598-6-39
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: The androgen receptor (AR) plays critical roles in both androgen-dependent and castrate-resistant prostate cancer (PCa). However, little is known about AR target genes that mediate the receptor's roles in disease progression. Results: Using Chromatin Immunoprecipitation (ChIP) Display, we discovered 19 novel loci occupied by the AR in castrate resistant C4-2B PCa cells. Only four of the 19 AR-occupied regions were within 10-kb 5'-flanking regulatory sequences. Three were located up to 4-kb 3' of the nearest gene, eight were intragenic and four were in gene deserts. Whereas the AR occupied the same loci in C4-2B (castrate resistant) and LNCaP (androgen-dependent) PCa cells, differences between the two cell lines were observed in the response of nearby genes to androgens. Among the genes strongly stimulated by DHT in C4-2B cells-D-dopachrome tautomerase (DDT), Protein kinase C delta (PRKCD), Glutathione S-transferase theta 2 (GSTT2), Transient receptor potential cation channel subfamily V member 3 (TRPV3), and Pyrroline-5-carboxylate reductase 1 (PYCR1)-most were less strongly or hardly stimulated in LNCaP cells. Another AR target gene, ornithine aminotransferase (OAT), was AR-stimulated in a ligand-independent manner, since it was repressed by AR siRNA knockdown, but not stimulated by DHT. We also present evidence for in vivo AR-mediated regulation of several genes identified by ChIP Display. For example, PRKCD and PYCR1, which may contribute to PCa cell growth and survival, are expressed in PCa biopsies from primary tumors before and after ablation and in metastatic lesions in a manner consistent with AR-mediated stimulation. Conclusion: AR genomic occupancy is similar between LNCaP and C4-2B cells and is not biased towards 5' gene flanking sequences. The AR transcriptionally regulates less than half the genes nearby AR-occupied regions, usually but not always, in a ligand-dependent manner. Most are stimulated and a few are repressed. In general, response is stronger in C4-2B compared to LNCaP cells. Some of the genes near AR-occupied regions appear to be regulated by the AR in vivo as evidenced by their expression levels in prostate cancer tumors of various stages. Several AR target genes discovered in the present study, for example PRKCD and PYCRI, may open avenues in PCa research and aid the development of new approaches for disease management.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Novel drugs targeting the androgen receptor pathway in prostate cancer
    Joaquin Mateo
    Alan Smith
    Michael Ong
    Johann S. de Bono
    Cancer and Metastasis Reviews, 2014, 33 : 567 - 579
  • [42] IDENTIFICATION OF TARGET GENES IN MINERALISING OSTEOBLASTS THAT ARE DIRECTLY REGULATED VIA THE ANDROGEN RECEPTOR
    Davey, R. A.
    Russell, P. K.
    Chiang, C.
    Chiu, M. W. S.
    Clarke, M. V.
    Zajac, J. D.
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 : S582 - S583
  • [43] Novel drugs targeting the androgen receptor pathway in prostate cancer
    Mateo, Joaquin
    Smith, Alan
    Ong, Michael
    de Bono, Johann S.
    CANCER AND METASTASIS REVIEWS, 2014, 33 (2-3) : 567 - 579
  • [44] Endostatin: A novel inhibitor of androgen receptor function in prostate cancer
    Lee, Joo Hyoung
    Isayeva, Tatyana
    Larson, Matthew R.
    Sawant, Anandi
    Cha, Ha-Ram
    Chanda, Diptiman
    Chesnokov, Igor N.
    Ponnazhagan, Selvarangan
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (05) : 1392 - 1397
  • [45] Endostatin is a novel inhibitor of androgen receptor function in prostate cancer
    Lee, Joo Hyoung
    Isayeva, Tatyana
    Larson, Matthew
    Chanda, Diptiman
    Chesnokov, Igor
    Ponnazhagan, Selvarangan
    CANCER RESEARCH, 2014, 74 (19)
  • [46] Androgen receptor: role and novel therapeutic prospects in prostate cancer
    Taplin, Mary-Ellen
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (09) : 1495 - 1508
  • [47] The androgen/androgen receptor axis in prostate cancer
    Bluemn, Eric G.
    Nelson, Peter S.
    CURRENT OPINION IN ONCOLOGY, 2012, 24 (03) : 251 - 257
  • [48] Prostate androgen-regulated gene: a novel potential target for androgen-independent prostate cancer therapy
    Xu, Xiao-Feng
    Zhou, Si-Wei
    Zhang, Xu
    Ye, Zhang-Qun
    Zhang, Jian-Hua
    Ma, Xin
    Zheng, Tao
    Li, Hong-Zhao
    ASIAN JOURNAL OF ANDROLOGY, 2006, 8 (04) : 455 - 462
  • [49] Natriuretic Peptide Receptor A as a Novel Target for Prostate Cancer
    Wang, Xiaoqin
    Raulji, Payal
    Mohapatra, Shyam S.
    Patel, Ronil
    Hellermann, Gary
    Kong, Xiaoyuan
    Vera, Pedro L.
    Meyer-Siegler, Katherine L.
    Coppola, Domenico
    Mohapatra, Subhra
    MOLECULAR CANCER, 2011, 10
  • [50] Cannabinoid receptor as a novel target for the treatment of prostate cancer
    Sarfaraz, S
    Afaq, F
    Adhami, VM
    Mukhtar, H
    CANCER RESEARCH, 2005, 65 (05) : 1635 - 1641